Get started
Author

Wendong Zhang

Observed names: W. Zhang, Zhang, Wendong
OpenAlex ID: A5017745708
Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).
2007 · Marcos de Lima, J. McMannis, et al. · Blood · 6
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas
2025 · Jiemiao Hu, Harjeet Singh, et al. · Proceedings of the National Academy of Sciences · 3
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen
2009 · G. Alatrash, B. Andersson, et al. · Transplantation and Cellular Therapy · 2
Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al. · Molecular Cancer Therapeutics · 1
PDF
High Rate Of De Novo Chronic Graft-Versus-Host (cGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS
2009 · R.M. Saliba, K.V. Komanduri, et al. · Transplantation and Cellular Therapy · 1
PDF
Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma
2026 · Brian Mooney, Xiaojie Chu, et al. · Cell Reports
Supplementary Figure 3 from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Supplementary Figure 2 from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Supplementary Figure 1 from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Supplementary Table 1 from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Data from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Supplemental Data from Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models
2026 · Yifei Wang, Zhongting Zhang, et al.
Abstract 7883: Surface CADM1 (Cell Adhesion Molecule 1) abundance predicts payload delivery and in-vitro efficacy of CADM1-GGFG-Exatecan ADC in osteosarcoma, aiding optimal candidate selection
2026 · Caterina Longo, Zhongting Zhang, et al. · Cancer Research
Abstract 7813: Antitumor activity of a B7-H3 antibody-drug conjugate in osteosarcoma patient-derived and metastatic models
2026 · Wendong Zhang, Adil Bahadir, et al. · Cancer Research
Abstract 5623: Novel mechanism for eliminating tumor collagens to boost efficacy by attIL12-TIL therapy in PDX sarcoma models
2026 · Jiemiao Hu, Harjeet Singh, et al. · Cancer Research
Abstract 7874: Dose-response efficacy of cell adhesion molecule 1 (CADM1)-GGFG-Exatecan vs CADM1-PEG3-VC-Exatecan in preclinical osteosarcoma models
2026 · Zhongting Zhang, Caterina Longo, et al. · Cancer Research
Adoptive transfer of membrane-anchored and tumor cell surface vimentin-targeted interleukin 12 armed TILs suppresses collagen expression to boost deep T-cell tumor infiltration 2033
2025 · Jiemiao Hu, Harjeet Singh, et al. · The Journal of Immunology
PDF
Pb1772 Tumor‐forming Plasmacytoid Dendritic Cells in Acute Myelomonocytic/monocytic Leukemia
2019 · L. Zhu, P. Wang, et al. · HemaSphere
Post-Hematopoietic Stem Cell Transplantation (HSCT) Outcomes in Patients With AML Transplanted Prior to Achieving Platelet Recovery
2009 · G. Alatrash, M. Pelosini, et al. · Transplantation and Cellular Therapy
Impact of Cytogenetics and Marrow Remission Status on Disease Progression in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Stem Cell Transplantation
2009 · E. Koca, R.M. Saliba, et al. · Transplantation and Cellular Therapy
PDF
15: The Impact of Resolved Hepatitis B Infection on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
2008 · C.A. Ramos, R.M. Saliba, et al. · Transplantation and Cellular Therapy
PDF
Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia
1992 · H. M. Kantarjian, M. Talpaz, et al. · Hämatologie und Bluttransfusion
Works count: 24
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type